Effects of Gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6006-6012

  Gregorc, Vanesa ^a   Ceresoli, Giovanni Luca ^a   Floriani, Irene ^b   Spreafico, Anna ^a   Bencardino, Katia Bruna ^a   Ludovini, Vienna ^c   Pistola, Lorenza ^c   Mihaylova, Zhasmina ^c   Tofanetti, Francesca Romana ^c   Ferraldeschi, Massimiliano ^c   Torri, Valter ^b   Cappuzzo, Federico ^d   Crinò, Lucio ^d   Tonato, Maurizio ^c   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Lab of Clin Research in Oncology   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

^d BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN TOXICITY; SURVIVAL TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644285519     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0770     Document Type: Article

References (34)

1. Ciardiello F, Caputo R, Bianco R, et al. Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by GEFTTINIB (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
2. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
3. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
4. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Final results from a phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). J Clin Oncol 2003;21:2237-46.
6. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003;290:2149-58.
7. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13S.
8. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-74.
9. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor Gefitinib ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-88.
10. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients with advanced EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Clin Oncol 2001;20:310a.
11. Cappuzzo F, Gregore V, Rossi E, et al. Gefitinib in pretreated non-small cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-63.
12. Mayes EL, Waterfield MD. Biosynthesis of the epidermal growth factor receptor in A431 cells. EMBO J 1984;3:531-7.
13. Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 1991;266:1716-20.
14. Wu JT, Astill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anals 1993;7:31-40.
15. Osaki T, Mitsudomi T, Oyama T, Nakanishi R, Yasumoto K. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 1995;108:157-62.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92:205-16.
17. Common toxicity criteria. National Institutes of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Bethesda, 1993.
18. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor Gefitinib in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002;20:110-24.
19. Carney WP, Burrell M, Morris LD, Hamer P. Normal levels of serum EGFR and decreases in several cancers. Proceedings of the American Association for Cancer Res 2002;43;240.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-69.
22. Calvo B, Caskey L, Earp H. Real-time fluorescent quantitative PCR reveals increased HER2, HER3, and unchanged HER1 (EGFR) mRNA expression levels in colon carcinomas. Proc 2001 Am Assoc Cancer Res Int Conf 2002;7:3761s.
23. Chou CK, Dull TJ, Russell DS, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 1987;262:1842-7.
24. Glenney JR Jr, Chen WS, Lazar CS, et al. Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies. Cell 1988;52:675-84.
25. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 1994;300:281-90.
26. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993;8:2917-23.
27. Lin CR, Chen WS, Kruiger W, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science 1984;224:843-8.
28. Decker SJ. Epidermal growth factor-induced truncation of the epidermal growth factor receptor. J Biol Chem 1989;264:17641-4.
29. Soulieres D, Senzer NN, Yokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of Erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
30. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000;18:3722-30.
31. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer pretreated with cisplatin-based chemotherapy. Lung Cancer 2004;44:231-9.
32. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of outcome? Oncology 2003;17:23-8.
33. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of Cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
34. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7.